开放与微创胸腺切除术治疗I至III期胸腺瘤的国家分析
该研究基于美国国家癌症数据库2010至2014年数据,比较开放与微创(胸腔镜及机器人)胸腺切除术治疗I至III期胸腺瘤的围手术期结局和总生存。共评估1223例胸腺切除术,其中317例(26%)为微创。倾向评分匹配分析显示微创组住院时间更短,在切缘阳性、30天再入院、30天死亡率及5年生存方面与开放组无显著差异。
要点
- 微创胸腺切除术与更短的中位住院时间相关。
- 倾向评分匹配后微创与开放组在切缘阳性、30天再入院、30天死亡及5年生存无显著差异。
- 微创胸腺切除术在I至III期胸腺瘤中未显示肿瘤学疗效劣于开放手术。
核心结论
- 微创胸腺切除术与更短的住院时间相关,且未增加切缘阳性、围手术期死亡、30天再入院率或降低总生存。
研究设计与样本
- 基于美国国家癌症数据库的回顾性队列研究,纳入2010至2014年临床I至III期胸腺瘤行胸腺切除术的患者1223例。
- 采用多变量Cox比例风险模型和倾向评分匹配分析,并按意向性治疗分析评估手术方式结局。
主要发现
- 1223例胸腺切除术中317例(26%)为微创,包括141例胸腔镜和176例机器人。
- 微创组中位住院时间3天(2-4天),开放组4天(3-6天),P < .001。
- 倾向评分匹配185对后,微创组中位住院时间仍为3天,开放组4天,P < .01。
- 匹配分析中切缘阳性P = .84,30天再入院P = .28,30天死亡P = .60。
- 匹配分析中5年生存率微创组89.4%,开放组81.6%,P = .20。
临床怎么用
- 对于临床I至III期胸腺瘤,微创胸腺切除术可作为开放手术的替代选择,与更短住院时间相关且未增加围手术期风险或降低生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The oncologic efficacy of minimally invasive thymectomy for thymoma is not well characterized. We compared short-term outcomes and overall survival between open and minimally invasive (video-assisted thoracoscopic and robotic) approaches using the National Cancer Data Base. METHODS: Perioperative outcomes and survival of patients who underwent open versus minimally invasive thymectomy for clinical stage I to III thymoma from 2010 to 2014 in the National Cancer Data Base were evaluated using multivariable Cox proportional hazards modeling and propensity score-matched analysis. Predictors of minimally invasive use were evaluated using multivariable logistic regression. Outcomes of surgical approach were evaluated using an intent-to-treat analysis. RESULTS: Of the 1223 thymectomies that were evaluated, 317 (26%) were performed minimally invasively (141 video-assisted thoracoscopic and 176 robotic). The minimally invasive group had a shorter median length of stay when compared with the open group (3 [2-4] days vs 4 [3-6] days, P < .001). In a propensity score-matched analysis of 185 open and 185 minimally invasive (video-assisted thoracoscopic + robotic) thymectomy, the minimally invasive group continued to have a shorter median length of stay (3 vs 4 days, P < .01) but did not have significant differences in margin positivity (P = .84), 30-day readmission (P = .28), 30-day mortality (P = .60), and 5-year survival (89.4% vs 81.6%, P = .20) when compared with the open group. CONCLUSIONS: In this national analysis, minimally invasive thymectomy was associated with shorter length of stay and was not associated with increased margin positivity, perioperative mortality, 30-day readmission rate, or reduced overall survival when compared with open thymectomy.
引用
- Yang CJ, Hurd J, Shah SA, et al. A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma. J Thorac Cardiovasc Surg. 2019. PMID: 32245668. doi:10.1016/j.jtcvs.2019.11.114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。